1. Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper
- Author
-
Bailly, Sarah, Cartron, Guillaume, Chaganti, Sridhar, Cordoba, Raul, Corradini, Paolo, Düll, Johannes, Ferrarini, Isacco, Osborne, Wendy, Rosenwald, Andreas, Sancho, Juan-Manuel, Tilly, Hervé, Van Den Neste, Eric, Viardot, Aandreas, Visco, Carlo, Universitat Autònoma de Barcelona, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - (SLuc) Centre du cancer, and UCL - (SLuc) Service d'hématologie
- Subjects
Cancer Research ,CD19 ,Oncology ,non-Hodgkin lymphoma ,Antigens, CD19 ,diffuse large B-cell lymphoma ,Humans ,Lymphoma, Large B-Cell, Diffuse ,Hematology ,General Medicine ,Expert Testimony ,relapsed/refractory - Abstract
Medical writing assistance was provided by Sarah Stowell of Alligent Europe (Envision Pharma Group), funded by Incyte Biosciences International Sàrl. The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti-CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B-cell lymphoma and consider approaches to the use of anti-CD19 therapy.
- Published
- 2022